General Pathology and Non-Reproductive Pathology Research Group

GENERAL PATHOLOGY AND NON-REPRODUCTIVE PATHOLOGY RESEARCH GROUP

Advancing Pathology for Cancer, Tropical Diseases, Travel-related Diseases

Brief Description

The General Pathology and Non-Reproductive Pathology Research Group is a multidisciplinary research platform dedicated to advancing translational pathology in oncology, tropical diseases, and emerging travel-related infections.

With over one decade of experience in diagnostic pathology, immunology, and molecular biology, our team integrates histopathology, immunohistochemistry, molecular diagnostics, and biomarker discovery to bridge laboratory findings with clinical decision-making.

We collaborate with academic institutions, hospitals, and international research partners to develop innovative diagnostic tools, identify prognostic and predictive biomarkers, and contribute to precision medicine—particularly in regions where cancer and tropical infectious diseases intersect.

Background

Pathology remains the cornerstone of modern medicine. The evolution from conventional morphologic diagnosis to molecular and immune-based classification has transformed disease stratification, therapeutic targeting, and prognostication.

In oncology, advances such as molecular classification and immune microenvironment profiling have significantly improved patient management. In breast cancer, for example, subtyping such as Triple-negative breast cancer has highlighted the importance of molecular and metabolic characterization in predicting metastasis and therapeutic response.

In neuro-oncology, updates from the World Health Organization classification emphasize integrated histomolecular diagnosis, particularly in entities such as Diffuse glioma.

Meanwhile, tropical and travel-related diseases continue to pose diagnostic and public health challenges, especially in endemic regions like Southeast Asia. Conditions such as Dengue fever, Malaria, and Tuberculosis require robust pathological and immunological investigation to improve early detection, severity prediction, and monitoring.

Despite technological progress, significant gaps remain:

• Limited integration of immunopathology and molecular biomarkers in routine diagnostics in low–middle income settings
• Insufficient characterization of tumor–immune–metabolic interactions in aggressive cancers
• Underexplored pathology-based biomarkers in tropical and emerging infectious diseases

Our research group was established to address these challenges through an integrated, translational, and globally collaborative approach.

Vision

To become a leading translational pathology research group in South East Asia, advancing precision diagnostics and biomarker-driven strategies for cancer and infectious diseases with global impact.

Mission

1. Advance Translational Pathology
   Integrate histopathology, immunology, and molecular biology into clinically relevant research.
2. Develop Biomarkers for Precision Medicine
   Identify diagnostic, prognostic, and predictive biomarkers in cancer and tropical diseases.
3. Strengthen Molecular and Immunopathology Platforms
   Expand capabilities in immunohistochemistry, digital pathology, and molecular profiling.
4. Foster International Collaboration
   Build sustainable partnerships with global research institutions and multidisciplinary consortia.
5. Capacity Building and Education
   Train young scientists and clinicians in advanced diagnostic and translational research methodologies.

Research Roadmap

Phase 1 (Years 1–2): Foundation and Biomarker Identification

• Establish integrated biobank for cancer and infectious diseases
• Immunohistochemical profiling of tumor microenvironment and inflammatory markers
• Molecular characterization of high-risk cancer subtypes
• Immune profiling in severe tropical infections

Key Outputs:
Peer-reviewed publications, biomarker panels, national research grants.

Phase 2 (Years 3–4): Translational Integration

• Multi-omics integration (genomic–proteomic–immunologic data)
• Development of predictive models for metastasis and severe infection outcomes
• Validation studies in multicenter cohorts
• Digital pathology and AI-assisted diagnostic modeling

Key Outputs:
International collaborations, predictive algorithms, patent submissions.

Phase 3 (Years 5+): Precision and Global Impact

• Clinical implementation of validated biomarker panels
• Personalized risk stratification tools
• Policy contribution for pathology-based diagnostic guidelines
• Regional center of excellence for cancer and tropical disease pathology

Key Outputs:
Guideline contributions, global consortium leadership.

Core Research Themes

• Tumor metabolism and metastatic potential
• Tumor–immune microenvironment profiling
• Immunopathology of tropical infections
• Biomarkers in travel-related emerging diseases
• Molecular diagnostics in resource-limited settings
• AI and digital pathology integration

Why It Matters

Cancer and infectious diseases remain leading causes of morbidity and mortality worldwide—particularly in tropical and developing regions. Precision pathology is no longer optional; it is essential.

By integrating morphological expertise with immunological and molecular innovation, our research group is committed to transforming pathology from a diagnostic endpoint into a predictive, personalized, and globally impactful discipline.

Research group member

Publication